Carisma Therapeutics, Inc. (CARM)
| Previous close | 1.4100 |
| Open | 1.3900 |
| Bid | 1.3800 x 300 |
| Ask | 1.4100 x 100 |
| Day's range | 1.3900 - 1.4399 |
| 52-week range | 1.3450 - 9.7660 |
| Volume | |
| Avg. volume | 172,437 |
| Market cap | 58.16M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1200 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.83 |
PR NewswireCarisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the first patient was dosed in its Phase 1 clinical trial evaluating CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy, for the treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).
Simply Wall St.Is There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?
Key Insights The projected fair value for Carisma Therapeutics is US$2.77 based on 2 Stage Free Cash Flow to Equity...
ZacksCarisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
CARISMA THERAP (CARM) delivered earnings and revenue surprises of -24.32% and 12.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
